Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › acthar

acthar

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of acthar

5 trials tracked of acthar: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 38 citations.

5Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 3 Phase 3 1 Other / NA 1
  1. Phase 4 Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease Completed · 38 cited
  2. Phase 4 Impact of Acthar on Everyday Life of Participants With Severe Keratitis Completed · 12 cited
  3. Phase 4 Adrenocorticotropic Hormone in Membranous Nephropathy Completed
  4. Phase 3 Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation Completed
  5. N/A Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate
Nephrology Phase III
Acthar studied in FSGS patients undergoing renal transplantation to measure recurrence rate Can a medication help prevent kidney disease from returning after transplant?
A prospective phase 3 study enrolled 15 renal transplant recipients with primary FSGS to evaluate Acthar.
A new kidney transplant study found that Acthar medication may lower the risk of FSGS returning to the new organ, offering hope to patients …
CT.gov Mar 30, 2026